ANNX vs IOVA โ Head-to-Head Terminal
6-dimension institutional benchmarking across valuation, multi-year operating margins, normalized momentum, and dealer gamma corridors.
Pillar 1 Executive Scorecard & Category Winner Tally
IOVA Captures Institutional Edge (2โ1 Pillars ยท 5โ3 Matrix Metrics)
Tradestie Institutional Equity Comparison Engine assigns the overall head-to-head edge to Iovance Biotherapeutics, Inc. Common Stock (IOVA) driven by superior Momentum & Technical, Options & Structure while ANNX counters with relative strength in Growth & Margin. Fundamentally, ANNX trades at N/M Forward P/E with 0.0% operating margin (+0.0% YoY revenue) versus IOVA at N/M Forward P/E and -60.8% operating margin (+80.1% YoY). In options structure, ANNX sits in BREAKDOWN (100th %ile IV; Dealer Gamma Walls on Pro) against IOVA sits in BREAKDOWN (35th %ile IV; Dealer Gamma Walls on Pro).
Pillar 2 Normalized Relative Return Performance (% Indexed to 0%)
Pillar 3 Operating Profitability Benchmark (Trailing 12-Month)
Pillar 4 Head-to-Head Fundamental & Valuation Matrix
| Institutional Metric | ANNX | IOVA | Criterion | Row Winner |
|---|---|---|---|---|
| Market Capitalization Scale | $747.8M | $3.6B | Larger Scale | IOVA |
| Trailing P/E Ratio Valuation | N/M | N/M | Lower Multiple | Tie |
| Forward P/E Ratio Valuation | N/M | N/M | Lower Multiple | Tie |
| Revenue Growth (YoY) Growth | +0.0% | +80.1% | Higher Growth | IOVA |
| Operating Margin (TTM) Profitability | 0.0% | -60.8% | Higher Margin | ANNX |
| Net Profit Margin Profitability | 0.0% | -58.2% | Higher Margin | ANNX |
| Return on Equity (ROE) Capital Efficiency | -130.8% | -29.1% | Higher ROE | IOVA |
| 52-Week Range Position Momentum | 18% ($3โ$7) | 40% ($2โ$15) | Stronger Trend | IOVA |
| Beta / 30D Volatility Risk Regime | 1.69ฮฒ ยท 63% Vol | 1.58ฮฒ ยท 140% Vol | Lower Realized Risk | ANNX |
| Unified Institutional Score Composite Signal | 43.5 / 100 (HOLD) | 55.0 / 100 (HOLD) | Higher Composite | IOVA |